- PRESS RELEASE
- May 10, 2013, 10:00 a.m. ET
Multiple clinical trials and pilot programs underscore growing interest in wireless patient monitoring technology
MINNEAPOLIS, May 10, 2013 /PRNewswire/ -- Preventice, Inc., a leading
developer of mHealth solutions, announced today the commercial
availability of its BodyGuardian Remote Patient Monitoring System
(BodyGuardian RMS). Preventice received 510(k) clearance from the U.S.
Food and Drug Administration (FDA) in August 2012, enabling the mobile
health solutions company to market BodyGuardian for use in detecting and
monitoring non-lethal cardiac arrhythmias for ambulatory patients.
Developed in collaboration with Mayo Clinic, the BodyGuardian System
uses sophisticated algorithms to support remote monitoring for
individuals with cardiac arrhythmias. The BodyGuardian System allows
physicians to monitor key biometrics outside of the clinical setting,
while patients go about their daily lives. A small body sensor attached
to the patient's chest collects important data, including ECG, heart
rate, respiration rate, and activity level. Patient data can then be
transmitted to physicians via mobile phone technology. This level of
remote patient monitoring can create a constant connection between
patients and their care teams.
Growing clinical demand for monitoring technology
According to a report from the American College of Cardiology, the
American Heart Association Task Force, and the European Society of
Cardiology Committee for Practice Guidelines, atrial fibrillation is the
most common form of arrhythmia and the incidence increases with age,
with stroke and heart failure the most common complications. In
addition, the American Heart Association currently estimates that six
million people in the United States have atrial fibrillation, and that
number is expected to grow to 12 to 15 million by 2050.
Remote patient monitoring can aid in the diagnosis of atrial
fibrillation by providing accessible ECG and rhythm monitoring in both
symptomatic and asymptomatic people as they go about their daily lives.
The technology can also support treatment efforts by allowing physicians
to screen for high-risk atrial fibrillation patients, to validate
treatment, show medication compliance, and monitor patients who are
adjusting to anticoagulation medication. While the cost for treating
atrial fibrillation--including hospitalization, in- and out-patient
physician care and medications--grew to $6.65 billion in 2005, the use
of remote monitoring technology by leading health care organizations has
been steadily on the rise and is expected to continue its upward
"There is a growing acceptance for monitoring patients outside the
hospital setting," said Jon Otterstatter, co-founder, president and CEO
of Preventice. "What sets the BodyGuardian RMS apart from other
monitoring systems is our expertise in creating a continually connected
environment between patients and clinical care teams, and our ability to
meet the security and privacy needs of patients and the health care
Preventice is experiencing this demand firsthand, and is currently
involved in multiple clinical trials in the United States and Europe to
quantify the impact of the BodyGuardian RMS on clinical care delivery.
Clinical pilots with the BodyGuardian RMS are currently underway in
the United States, France, and Italy targeting the use of remote
monitoring for various treatment scenarios including:
-- Post-surgical cardiac patients to evaluate how monitoring cardiac rhythms
remotely influence all phases of hospital recovery,
-- Patients with congestive heart failure to determine early warning of
decompensated heart failure and delivery of more timely interventions
that can prevent more serious and expensive complications, and
-- 24/7 continuous monitoring of non-surgical, infrequently symptomatic
patients as they go about their daily lives, with the objective of
detecting potential arrhythmias by tracking ECG, respiratory rate and
In good company: Strategic partnerships
According to Otterstatter, the strength of the BodyGuardian RMS comes
from the enviable ecosystem of partners that Preventice has established,
which has allowed it to build a remote monitoring platform that is
secure, reliable and scalable.
"From day one, we made it a priority to affiliate the Preventice brand
with leaders in health care, wireless devices, sensor technology, and
ISO quality manufacturing processes," said Otterstatter. "As a result,
we have built a remote monitoring platform that meets the most stringent
privacy and security standards, that is reliable in a variety of
clinical and non-clinical settings and that exceeds the usability
expectations of today's sophisticated consumers."
For example, Otterstatter noted, that the BodyGuardian RMS was
developed in collaboration with Mayo Clinic (which developed the
algorithms on which the BodyGuardian RMS technology is based),
STMicroelectronics (which provided the sensor technology), and Samsung
Electronics (which provided the dedicated wireless environment that
contributes to the security and clinical reliability of the BodyGuardian
Preventice has licensed the remote monitoring algorithms for the
BodyGuardian Remote Monitoring System from Mayo Clinic. The BodyGuardian
System detects, records and wirelessly transmits physiological data to
support remote monitoring of non-lethal, cardiac arrhythmias in
ambulatory patients. Data is transmitted to the Preventice mHealth
platform, where it can be stored for later retrieval.
The BodyGuardian sensor adheres to the patient's skin and is smaller
than a cell phone, giving patients complete mobility and freedom to go
about their normal lives without restriction. Physicians and medical
professionals can securely view the captured medical information
anytime, any place on devices such as the iPad(R), or online. Physicians
can retrieve patient data and reports, or choose to receive alerts
based on changes in select biometrics.
Preventice, a leading developer of mobile health applications and
remote monitoring systems, aims to engage patients with their care plans
and close the patient engagement gap--the half trillion dollar cost
created by patients failing to follow individual care plans. Technology
from Preventice creates a continuous connection and exchange of data
between health care providers, life science companies and patients.
Current applications from Preventice address high-cost and chronic
conditions and health management opportunities, including prescription
medication management, cardiac care, sleep apnea, diabetes management,
and migraine headaches. Preventice is headquartered in Minneapolis, with
offices in Rochester, Minn., and Fargo, N.D. For more information,
For more information:
Barbara Tabor, APR
Tabor Communications Consulting for Preventice
SOURCE Preventice, Inc.
/Web site: http://www.preventice.com
The Wall Street Journal news department was not involved in the creation of this content.